In 2021 we saw deals move away from the massive megamergers of 2019 to smaller collaboration and partnership agreements. In this article, European Pharmaceutical Review’s Hannah Balfour discusses the key deals of last year, whether the trend of high volume but small value will continue in 2022, and the motivations…
List view / Grid view
The new manufacturing facility will support production and development of cannabis-based medicines in the UK.
GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
In this article, EPR summarises the list of 10 recommendations for the UK Government, published by experts in the medicinal cannabis industry, to ensure the UK capitalises on the opportunities afforded by the market.
The Queen’s Award for Enterprise in Innovation was awarded to GW for leadership in cannabinoid science and development of prescription cannabis-based medicines.
According to Jazz Pharmaceuticals, the combined company will be a leader in neuroscience, well positioned to maximise the value of its diversified portfolio.
GW Pharmaceuticals's Epidyolex (cannabidiol) has been changed from a Schedule 2 drug to a Schedule 5 drug, making it exempt from virtually all controlled drug requirements.
Researchers have revealed the countries which spend the most on R&D as compared to revenue, as well as the companies in the UK investing in research.
Following guidance from the drugs advisory body NICE, two cannabis-based medications have been approved for treatment by the NHS in England.
The cannabidiol-based treatment EPIDYOLEX has been granted marketing authorisation from the European Commission.
NICE and GW Pharma will work together to address the issues highlighted in its evaluation of cannabidiol for treating two types of epilepsy.
EMA’s human medicines committee had cleared the cannabidiol oral solution, Epidiolex, for use to treat seizures.
Cannabidiol was shown in a new large-scale, randomised, controlled trial to significantly reduce the number of dangerous seizures in patients with a severe form of epilepsy...
Puration plans to displace pharmaceutical market leader, GW Pharmaceuticals, as part of strategy to grow US cannabis market
21 April 2017 | By Niamh Marriott, Junior Editor
Taking cannabidiol may cut seizures in half for some children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy...